Abstract
The rare benign giant cell tumour of bone (GCTB) is defined by an almost unique G34W oncohistone mutation in the H3.3 histone gene. Here we reveal the genomic and methylation patterns underlying the rare clinical phenomena of benign metastases and malignant transformation of GCTB.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The Tom Prince Cancer Trust UK Medical Research Council grant (MR/M00094X/1) The Wellcome Trust Skeletal Cancer Action Trust UK the Royal National Orthopaedic Hospital NHS Trust R&D Department the Rosetrees and Stoneygate Trusts (M46 F1) the Pathological Society of Great Britain and Ireland (PL) and the Bone Cancer Research Trust A.M.F is a NIHR senior investigator AMF and N.P. were supported by the National Institute for Health Research UCLH Biomedical Research Centre UCL Experimental Cancer Centre. the Francis Crick Institute which receives its core funding from Cancer Research UK (FC001202) the UK Medical Research Council (FC001202), and the Wellcome Trust (FC001202). Personal fellowships have been granted to S.B. (Wellcome Trust Intermediate Clinical Research Fellowship, St. Baldricks Foundation Robert J. Arceci International Innovation Award), I.L. (Lundbeck Foundation, award 2018-3018), P.J.C. (Wellcome Trust Senior Clinical Research Fellowship), N.P. (CRUK Clinician Scientist Fellowship (grant number 18387). and E.M. (CRUK Career Development Fellow), M.W.F. (from a CRUK accelerator award C422/A21434), J.D. (Research Foundation Flanders, FWO Postdoctoral Fellowship; European Union Horizon 2020 Research and Innovation programme, MSCA 703594 DECODE), M.T. (European Union Horizon 2020 Research and Innovation programme postdoctoral fellowship, MSCA 747852 SIOMICS). P.V.L. is a Winton Group Leader in recognition of the Winton Charitable Foundation support towards the establishment of The Francis Crick Institute. We are grateful to the RNOH Musculoskeletal Pathology Biobank team for consenting patients and accessing samples. We thank all the patients for participating in our research and the clinical teams involved in their care.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
National Research Ethics Service (NRES) Committee Yorkshire & The Humber Leeds East (15/YH/0311)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The authors declare that all data supporting the findings of this study are available within the article and its supplementary files or from the corresponding author on reasonable request.
